SEATTLE, WA and CAMBRIDGE, UK — Pluristyx, a leading provider of clinical-grade induced pluripotent stem cell (iPSC) solutions, and Qkine, a pioneer in the manufacture of high-purity, animal-free growth factors and cytokines, today announced a distribution agreement to support streamlined and efficient R&D and manufacturing of differentiated cells and tissues from iPSC. This collaboration will provide researchers, product manufacturers, and therapeutic developers with a streamlined, high-performance workflow, pre-qualified to deliver reliable differentiation of iPSCs into product cells and tissues. [Read more…]
Cartherics and Catalent Expand Commercial License Agreement
MELBOURNE, Australia & TAMPA, FL – Cartherics Pty Ltd, a biotech company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, has announced an enhanced partnership.
The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced pluripotent stem cells (iPSC) line for the manufacture and commercialization of Cartherics’ iPSC-derived Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies. The agreement supports Cartherics’ mission to develop immune cell therapy products for the treatment of cancer and endometriosis. [Read more…]
UCB’s $1.15 Billion Bet on Neurona Signals Major Push into Pluripotent Stem Cell–Derived Cell Therapy
In one of the largest regenerative medicine deals of 2026 to date, UCB has announced plans to acquire Neurona Therapeutics in a transaction valued at an astounding price tag: up to $1.15 billion. The deal includes $650 million upfront, with an additional $500 million tied to future milestones, underscoring the scale of UCB’s commitment to next-generation therapeutic modalities. [Read more…]
Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges
Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies — directly applicable to biotech and pharma iPSC programs.
Toulouse, 2026 April 16th – Scale-up remains one of the most critical unsolved challenges in iPSC-derived cell therapy. Despite strong clinical promise, most manufacturing processes today can only supply material for a very limited number of patients — a bottleneck that limits clinical progression and commercial viability across the field. [Read more…]
iPSC Therapies Make History: Japan Authorizes World’s First Two iPSC-based Cell Therapies
Recently, the world witnessed the approval of the world’s first two iPSC-derived medicines, as Japan’s health ministry panel authorized their commercialization on February 19, 2026. The approved therapies are ReHeart, developed by Cuorips Inc., a regenerative medicine company spun out of research at Osaka University, and Amchepry, developed by Sumitomo Pharma Co., Ltd. in collaboration with Racthera Inc. [Read more…]
- 1
- 2
- 3
- …
- 18
- Next Page »